الفهرس 
H. pylori infectionOnly 14 pages are availabe for public view
 |  | from | 119 |  |  |
| | | from | 119 | | |
Abstract
Background: H. pylori infection is a leading etiological factor for various gastroduodenal diseases, including chronic gastritis, peptic ulcers and duodenal ulcers, as well as adenocarcinoma and MALT lymphoma of the stomach. In the last decad, there has been a negative trend in the effectiveness of classic eradication therapy regimens of H.pylori, which has largely been determined by the emergence and spread of antibiotic resistance.
Aim of the Work: Study the effect of adding Rebamipide on the eradication therapy for helicobacter pylori infection in Egyptian patients.
Patients and Methods: This study included 100 patients with H.Pylori infection who had been confirmed by tissue histopathology.
Results: Regarding the outcome, there was a statistically significant difference between the two groups (p= 0.027) as in Rebamipide group, there was 12% cases had positive results and 88% cases had negative results while in control group, there was 30% cases had positive results and 70% cases had negative results. Regarding side effects, there was no statistically significant difference between the two groups (p= 0.360). one case in Rebamipide group experienced mild skin rash at 1st day of treatment because of allergy to rebamipide and patient was completely free of symptoms after two days without stopping treatment.
Conclusion: This study demonstrated that the addition of rebamipide to H. pylori eradication regimens significantly increases the effectiveness of treatment. Based on our findings, abdominal discomfort was observed significantly higher in control group, there was a statistically significant difference between the two groups (more to rebamipide group) regarding outcome and there was no statistically significant difference between the two studied groups regarding side effects